147 related articles for article (PubMed ID: 22068354)
21. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.
Hong J; Kim JY; Ahn HK; Lee SM; Sym SJ; Park J; Cho EK; Ahn JY; Park S; Lee SP; Shin DB; Lee JH
Support Care Cancer; 2013 Apr; 21(4):1145-52. PubMed ID: 23111943
[TBL] [Abstract][Full Text] [Related]
22. Prediction of adverse events in patients receiving rapid rituximab infusion: validation of a predictive model.
Lang DS; Fong CC
Clin J Oncol Nurs; 2014 Feb; 18(1):89-92. PubMed ID: 24476730
[TBL] [Abstract][Full Text] [Related]
23. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases.
Ojeda-Uribe M; Afif N; Dahan E; Sparsa L; Haby C; Sibilia J; Ternant D; Ardizzone M
Clin Rheumatol; 2013 May; 32(5):695-700. PubMed ID: 23292481
[TBL] [Abstract][Full Text] [Related]
24. Rapid infusion rituximab changing practice for patient care.
Al Zahrani A; Ibrahim N; Al Eid A
J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
[TBL] [Abstract][Full Text] [Related]
25. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
[TBL] [Abstract][Full Text] [Related]
26. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.
Mishra R; Singh V; Pritchard CH
Rheumatol Int; 2011 Apr; 31(4):481-4. PubMed ID: 20091035
[TBL] [Abstract][Full Text] [Related]
27. Use of a pharmacy protocol to convert standard rituximab infusions to rapid infusion shortens outpatient infusion clinic visits.
Swan JT; Zaghloul HA; Cox JE; Murillo JR
Pharmacotherapy; 2014 Jul; 34(7):686-94. PubMed ID: 24706572
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular adverse events complicating the administration of rituximab: report of two cases.
Passalia C; Minetto P; Arboscello E; Balleari E; Bellodi A; Del Corso L; Molinari E; Ponassi I; Oneto C; Sicbaldi V; Ghio R
Tumori; 2013; 99(6):288e-92e. PubMed ID: 24503806
[TBL] [Abstract][Full Text] [Related]
29. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
30. [Rituximab in rheumatoid arthritis: a systematic review of efficacy and safety].
Hernández-Cruz B; García-Arias M; Ariza Ariza R; Martín Mola E
Reumatol Clin; 2011; 7(5):314-22. PubMed ID: 21925447
[TBL] [Abstract][Full Text] [Related]
31. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.
Vinod SS; Reed AB; Maxwell J; Cron RQ; Stoll ML
Pediatr Rheumatol Online J; 2018 Mar; 16(1):16. PubMed ID: 29523211
[TBL] [Abstract][Full Text] [Related]
32. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X; Gottenberg JE; Ravaud P; Combe B
Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases.
Vikse J; Jonsdottir K; Kvaløy JT; Wildhagen K; Omdal R
Rheumatol Int; 2019 Jun; 39(6):1083-1090. PubMed ID: 30923955
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
[TBL] [Abstract][Full Text] [Related]
35. Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy.
Combier A; Nocturne G; Henry J; Belkhir R; Pavy S; Le Tiec C; Descamps E; Seror R; Mariette X
Rheumatology (Oxford); 2020 Jun; 59(6):1347-1354. PubMed ID: 31613955
[TBL] [Abstract][Full Text] [Related]
36. Does rituximab increase the incidence of infectious complications? A narrative review.
Kelesidis T; Daikos G; Boumpas D; Tsiodras S
Int J Infect Dis; 2011 Jan; 15(1):e2-16. PubMed ID: 21074471
[TBL] [Abstract][Full Text] [Related]
37. Systemic adverse events following rituximab therapy in patients with Graves' disease.
El Fassi D; Nielsen CH; Junker P; Hasselbalch HC; Hegedüs L
J Endocrinol Invest; 2011; 34(7):e163-7. PubMed ID: 21169731
[TBL] [Abstract][Full Text] [Related]
38. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
[TBL] [Abstract][Full Text] [Related]
39. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
40. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
